CJC-1295 and ipamorelin side effects: what the small studies recorded and what users report

The side-effect questions about CJC-1295 and ipamorelin tend to circle the same list: flushing after the shot, hunger, water retention, numbness or tingling, sleep and blood sugar. Some of those match what the small human studies actually recorded. Others are borrowed from growth hormone itself and were never measured for these two peptides. This page sorts them, labeling each side effect as studied (recorded in a published human trial), reported (from what users post publicly) or expected but not measured, and gives the frequency wherever a study stated one.

What are CJC-1295 and ipamorelin?

CJC-1295 and ipamorelin are two synthetic peptides that make the pituitary gland release more of the body’s own growth hormone (GH), which then raises IGF-1. CJC-1295 is a long-acting copy of growth hormone-releasing hormone (GHRH); the version used in the human studies carries a “drug affinity complex” (DAC) that binds to blood albumin and gives it a half-life of about six to eight days (Teichman et al., 2006). Ipamorelin is a five-amino-acid peptide that acts on the ghrelin receptor and produces a short GH pulse, with a half-life of about two hours in healthy men (Gobburu et al., 1999). Our guide to what CJC-1295 and ipamorelin do covers the mechanism and the research in full.

Why do lifters use CJC-1295 and ipamorelin together?

Lifters pair them because the two act on different receptors, so the stack is pitched as a stronger, more “natural” GH pulse for recovery, sleep and body composition. A 2026 endocrinology review notes that in fitness discussions ipamorelin is frequently paired with CJC-1295, typically the form without DAC, but says this practice is largely driven by anecdote and that controlled evidence for synergy or body-composition benefits in healthy people remains limited (Dominikowski et al., 2026). That gap matters for side effects too: none of the trials below gave the two together, so every number on this page comes from one peptide or the other given alone.

How strong is the side-effect evidence?

The evidence level is small, short human trials, none in lifters. For CJC-1295, three published studies gave the DAC form to a combined 63 healthy adults, 87% of them men, and 73% of them received a single injection, according to the FDA’s 2024 review of the published safety data (FDA briefing document, CJC-1295, 2024). For ipamorelin, there is one dose-ranging hormone study in 48 healthy men, six on ipamorelin and two on placebo at each of five dose levels, each given a single 15-minute infusion (Gobburu et al., 1999; FDA briefing document, ipamorelin, 2024), and one phase 2 trial in 114 patients recovering from bowel surgery, who received it intravenously for up to seven days (Beck et al., 2014). The 2026 review puts both peptides in the second of its four evidence tiers, with phase 1 or 2 human data but no performance or body-composition trials, and puts CJC-1295 without DAC, the form most often stacked, in its lowest tier: no peer-reviewed human studies at all (Dominikowski et al., 2026).

What side effects did the CJC-1295 trials record?

The CJC-1295 trials recorded injection-site reactions in most volunteers, plus headache, flushing, loose stools and a faster heart rate, many of them short-lived and more common at higher doses. The main paper ran two randomized, placebo-controlled trials and reported no serious adverse reactions, describing CJC-1295 as relatively well tolerated, particularly at the lower doses tested (Teichman et al., 2006). The FDA’s 2024 summary of that paper gives the detailed rates, mostly from the first, single-dose trial (FDA briefing document, CJC-1295, 2024):

• Injection-site reactions (irritation, redness, hardening, pain or itching) in about 70% of people on CJC-1295 and rarely on placebo, more severe or longer-lasting at higher doses. In the second, multiple-dose trial, every person on CJC-1295 had them, but so did three of the four people on placebo (mild redness).
• Hive-like rashes at the injection site in almost 30%, not dose related.
• Headache in 63% on CJC-1295 versus 14% on placebo in the first trial; in the second, 20% to 80% depending on the dose group, versus 50% on placebo.
• Loose stools or diarrhea in 43%, rising to 45% and 100% in the two highest single-dose groups.
• Flushing, warmth and brief drops in blood pressure in 30%, none on placebo.
• Nausea or abdominal pain in 20% in the second trial, none on placebo.
• Isolated events: one person had brief involuntary leg-muscle contractions and some loss of coordination after a second dose, and two had brief dizziness with low blood pressure after the first dose that did not recur.

The same summary says the authors found no consistent changes in blood or urine tests, including glucose and liver tests, or in heart tracings (ECGs). A separate study in healthy men recorded a dose-dependent rise in heart rate and brief redness and tenderness at the injection site (Ionescu and Frohman, 2006; side effects as summarized in the FDA briefing document).

Does CJC-1295 cause flushing?

Yes, flushing is one of the best-documented CJC-1295 side effects, recorded in the trials and also reported by users. In the multiple-dose trial it occurred only in people on CJC-1295, began within 30 minutes of the injection and faded within one to two hours, and it rose with dose: 40% after low-dose and 100% after high-dose injections (FDA briefing document, CJC-1295, 2024). That matches the community picture, where one user described intense flushing early on that faded after lowering the dose (Community Insights summary of public X posts, July 2026).

What side effects did the ipamorelin trials record?

Ipamorelin’s one patient trial found side effects at rates close to placebo overall, with a few that leaned toward the drug. In 114 bowel-surgery patients, 87.5% on ipamorelin and 94.8% on placebo had at least one side effect, and the authors concluded it was well tolerated at the dose used (Beck et al., 2014). The FDA’s 2024 review of that trial lists the differences (FDA briefing document, ipamorelin, 2024):

• Most common effects were nausea, vomiting and abdominal bloating, similar in both groups and numerically lower on ipamorelin. These are typical after bowel surgery.
• Low potassium in 12.5% on ipamorelin versus 3.4% on placebo.
• Insomnia in 10.7% versus 5.2%.
• High blood sugar at discharge in 14.3% versus 8.6%.
• Serious adverse events (including infections, leaks at the surgical join and readmissions) in 17.9% versus 15.5%.
• Two deaths in ipamorelin-treated patients, both after complications of the bowel surgery; the FDA review says it is unclear whether they were related to ipamorelin.

The earlier hormone study in healthy men did not report any side effects (Gobburu et al., 1999, as noted in the FDA briefing document). The FDA’s adverse-event database held only two non-serious reports for ipamorelin products through September 2023: headache and watery eyes with a nasal spray, which the report linked to a product-quality problem, and elbow pain in a man injecting ipamorelin combined with sermorelin (FDA briefing document, ipamorelin, 2024).

Side effects at a glance: studied, reported or not measured

The table sets each side effect people ask about against the kind of evidence behind it. “Studied” means a published human trial recorded it; “reported” means it comes from public posts; “not measured” means no human study of these peptides looked for it.

CJC-1295 and ipamorelin side effects by source type. Trial rates from the FDA’s 2024 summaries of Teichman et al. (2006), Ionescu and Frohman (2006) and Beck et al. (2014); community reports from Recomp Lab Community Insights summaries of public X posts, July 2026.

Attribute	Seen with	Source type	How often (if stated)
Injection-site reactions	CJC-1295	Studied	About 70% (rare on placebo); all active subjects in a second trial
Headache	CJC-1295	Studied	63% vs 14% on placebo; 20% to 80% vs 50% in a second trial
Flushing and warmth	CJC-1295	Studied and reported	30%; 40% at low dose and 100% at high dose
Loose stools or diarrhea	CJC-1295	Studied	43%; up to 100% at the highest dose
Faster heart rate	CJC-1295	Studied	Dose dependent; no rate stated
Low potassium	Ipamorelin	Studied (surgical patients)	12.5% vs 3.4% on placebo
Insomnia or worse sleep	Ipamorelin; CJC-1295	Studied (ipamorelin); reported (both)	10.7% vs 5.2% on placebo
High blood sugar	Ipamorelin	Studied (surgical patients)	14.3% vs 8.6% at discharge; no consistent glucose change in CJC-1295 trials
Hunger	Ipamorelin	Animal study only	Not studied as a side effect in humans; secretagogue-treated mice ate more
Water retention, swelling	Neither	Not measured	Documented for tesamorelin and GH, not these two
Numbness or tingling	Neither	Not measured	Documented for tesamorelin, not these two
Bloodshot eyes, exhaustion	CJC-1295	Reported (one user)	No rate

Does ipamorelin make you hungry?

No human ipamorelin study has looked at hunger as a side effect, so the honest answer is “possibly, but unproven.” The one patient trial assessed appetite only as a sign of gut recovery after bowel surgery (FDA briefing document, ipamorelin, 2024). The concern comes from the receptor: ipamorelin acts where the hunger hormone ghrelin acts. In mice, twice-daily ipamorelin increased body fat, secretagogue treatment raised food intake, and the authors concluded the fat gain was independent of growth hormone and may involve increased feeding (Lall et al., 2001). The 2026 review rates the appetite signal as consistent for the older ghrelin-receptor peptides GHRP-2 and GHRP-6 but weaker for ipamorelin (Dominikowski et al., 2026). That puts the popular claim that ipamorelin has “no hunger” effect somewhere between plausible and untested, not established.

Do CJC-1295 and ipamorelin cause water retention or numbness?

Water retention and numbness are expected from raising growth hormone, but they were not recorded in the CJC-1295 or ipamorelin studies. The 2026 review says fluid-retention effects (swelling, tingling, joint and muscle aches) are documented in peer-reviewed human studies only for tesamorelin, and that comparable findings were not identified for the other GH peptides, while cautioning that the shared mechanism warrants care (Dominikowski et al., 2026). For scale, tesamorelin’s label lists peripheral swelling in 6% versus 2% on placebo, tingling in 5% versus 2% and numbness in 4% versus 2% (Egrifta WR label, DailyMed), and a systematic review of GH itself in healthy young adults found soft-tissue swelling and fatigue more often than in controls (Liu et al., 2008).

Part of the gap is exposure. Most of the CJC-1295 volunteers got one injection and the ipamorelin patients about a week of treatment after surgery, while tesamorelin’s swelling and tingling figures come from the first 26 weeks of daily use. Months of repeated dosing, the pattern lifters actually follow, has not been studied for either peptide. The FDA’s reviews of both peptides note that because they raise GH and IGF-1, risks similar to those on approved growth-hormone labels, which include fluid retention and glucose intolerance, may apply (FDA briefing document, CJC-1295, 2024; FDA briefing document, ipamorelin, 2024). Our page on tesamorelin side effects shows what that looks like when it is actually measured.

What are the downsides of CJC-1295?

The main downsides of CJC-1295 are frequent short-term side effects, a near-total lack of long-term data and almost no human data on the form most people use. In the trials, injection-site reactions, headache, flushing and loose stools were common, and most effects grew with dose (FDA briefing document, CJC-1295, 2024). A phase 2 trial in 192 people with HIV-related fat changes was stopped after a participant developed chest discomfort two hours after an 11th weekly dose, was found to be having a heart attack and died, according to the news reports the FDA review summarized; the attending physician’s most likely explanation was undiagnosed coronary artery disease, and the data were never published (FDA briefing document, CJC-1295, 2024). Beyond that, the review notes there are no long-term safety data and no human studies of CJC-1295 without DAC (Dominikowski et al., 2026).

Does CJC Ipamorelin affect testosterone?

None of the human studies covered here reported testosterone, so they give no evidence that the stack raises or lowers it. The CJC-1295 trials measured GH and IGF-1 as their main outcomes (Teichman et al., 2006), and in the founding ipamorelin research in pigs, none of the GH-releasing peptides tested, ipamorelin included, changed LH or FSH, the pituitary hormones that drive testosterone production (Raun et al., 1998). That points away from a direct effect, but it is an animal finding; if testosterone is your concern, our page on peptides while on TRT covers how GH peptides sit alongside testosterone therapy.

Does ipamorelin affect cortisol or prolactin?

The research suggests ipamorelin largely spares cortisol and prolactin, which is the basis of its “clean” reputation. In pigs, ipamorelin did not raise ACTH or cortisol beyond what GHRH did, even at more than 200 times the dose needed for GH release, while the older peptides GHRP-2 and GHRP-6 did (Raun et al., 1998). The 2026 review describes ipamorelin as “sparing” on both hormones and reports that a phase 1 study in healthy adults found no significant effects on other pituitary or adrenal hormones (Dominikowski et al., 2026). This is the one community claim about ipamorelin that the literature broadly supports.

How do CJC-1295 and ipamorelin side effects compare with tesamorelin?

The three are not easy to rank, because tesamorelin’s side effects come from trials with hundreds of patients over months, while CJC-1295 and ipamorelin were tested in small groups for days or weeks. All three raise GH and IGF-1, so the same class concerns apply; the difference is how much was actually measured.

How much is known about side effects across three GH-raising peptides. Sources: FDA 2024 briefing documents for CJC-1295 and ipamorelin, the Egrifta WR label and Dominikowski et al., 2026.

Attribute	CJC-1295 (DAC)	Ipamorelin	Tesamorelin
Human safety data	63 healthy adults, mostly one injection	Healthy men (one infusion); 114 surgical patients (up to 7 days)	Hundreds of patients, placebo-controlled, up to 52 weeks
Most common recorded effects	Injection-site reactions, headache, flushing, loose stools	Nausea, vomiting, bloating (similar to placebo after surgery)	Injection-site reactions, joint pain, swelling, muscle aches, tingling
Fluid retention and numbness	Not measured	Not measured	Documented on the label
Blood sugar	No consistent change in short trials	More high blood sugar than placebo after surgery	Labeled warning
Long-term data	None	None	Up to 52 weeks in its approved use

Does the source of the vial change the risk?

It can, because a peptide’s side effects depend on what is actually injected. In a laboratory analysis of falsified peptide drugs bought from suspected illegal internet pharmacies, researchers found wide variation in the amount of drug per unit, purity ranging from 5% to 75% for one group of peptides, and arsenic and lead contamination, with several samples at up to ten times the limit for injectable drugs (Janvier et al., 2018). The FDA’s ipamorelin review also noted that one of its two adverse-event reports was thought to stem from a product-quality problem (FDA briefing document, ipamorelin, 2024). None of the trial numbers above describe what an unregulated vial will do.

What the community is saying about CJC-1295 and ipamorelin side effects

In our summaries of public X posts, side effects are one recurring theme alongside stacks, rankings and timing. Our Community Insights summaries cover 17 public posts about CJC-1295 (July 13 to 19, 2026) and 16 about ipamorelin (July 15 to 16, 2026); these are anecdotes, not evidence.

• Flushing. One user described intense flushing early on that faded after lowering the dose. This is the report that best matches the trial data.
• Sleep and fatigue. One person said CJC-1295 wrecked their sleep and left them exhausted with bloodshot eyes, something they did not get from tesamorelin; another said GH secretagogues, ipamorelin included, worsened their sleep. The ipamorelin trial’s higher insomnia rate (10.7% versus 5.2%) is at least consistent with this.
• “Mostly mild.” Commenters cite a human trial with side effects in 94% of participants, mostly mild. We could not confirm the 94% figure in the sources we checked, but the direction holds: the FDA summary shows high rates of individual effects (headache in 63%, injection-site reactions in about 70%), and the trial authors called CJC-1295 relatively well tolerated.
• The “clean” peptide. A widely shared post called ipamorelin a starter peptide with no cortisol, prolactin or hunger effects. The cortisol and prolactin part fits the research; the hunger part has not been tested in people.
• Long-term fears. One poster called insulin resistance and high IGF-1 the two most cited fears about long-term GH peptide use and argued they are often overstated, while others link the DAC form’s constant GH elevation to insulin resistance and joint pain. No study has settled it either way.

Not mentioned in our summaries: water retention and numbness. That does not mean users never get them; it means they did not come up in this sample, and, as above, the trials did not measure them either.

The bottom line on CJC-1295 and ipamorelin side effects

The studied side effects of CJC-1295 are mostly short-term and dose-related: injection-site reactions, headache, flushing and loose stools. Ipamorelin looked close to placebo in its one patient trial, apart from more low potassium, insomnia and high blood sugar. The side effects lifters worry about most over months of use (water retention, numbness, hunger, blood sugar drift) are the ones no study of these two peptides has followed over that kind of time frame, so they remain expected rather than proven. For the wider picture across GH peptides, see our guide to realistic expectations and side effects for GH peptides, and the hub overviews of CJC-1295 and ipamorelin.

Status (CJC-1295 and ipamorelin): Not FDA-approved; sold by some telehealth providers as a compounded prescription. What this status means.

Educational information only, not medical advice. Side-effect figures come from the published trials linked above and from the FDA’s 2024 briefing documents summarizing them; the community summary reflects public posts on X analyzed in July 2026. Updated October 12, 2026. This page is drafted with AI assistance and checked against the cited primary sources before publication.